Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioRestorative Therapies (BRTX) Gross Profit (2016 - 2025)

BioRestorative Therapies (BRTX) has disclosed Gross Profit for 9 consecutive years, with $1230.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Gross Profit fell 99.43% year-over-year to $1230.0, compared with a TTM value of $357853.0 through Sep 2025, up 1.59%, and an annual FY2024 reading of $372928.0, up 155.78% over the prior year.
  • Gross Profit was $1230.0 for Q3 2025 at BioRestorative Therapies, down from $294571.0 in the prior quarter.
  • Across five years, Gross Profit topped out at $294571.0 in Q2 2025 and bottomed at $1230.0 in Q3 2025.
  • Average Gross Profit over 3 years is $86068.9, with a median of $39961.0 recorded in 2024.
  • Peak annual rise in Gross Profit hit 256.58% in 2025, while the deepest fall reached 99.43% in 2025.
  • Year by year, Gross Profit stood at $19300.0 in 2023, then surged by 107.05% to $39961.0 in 2024, then tumbled by 96.92% to $1230.0 in 2025.
  • Business Quant data shows Gross Profit for BRTX at $1230.0 in Q3 2025, $294571.0 in Q2 2025, and $22091.0 in Q1 2025.